ArticleClinical rheumatology2018
The incidence, prevalence, and survival of systemic sclerosis in the UK Clinical Practice Research Datalink.
Article in Clinical rheumatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 53 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- The 2024 British Society for Rheumatology guideline for management of systemic sclerosis.Rheumatology (Oxford, England) · 2024Guideline
- Oral rehabilitation with dental implants in patients with systemic sclerosis: A systematic review.Immunity, inflammation and disease · 2023Pooled it
- Incidence and prevalence of systemic sclerosis globally: a comprehensive systematic review and meta-analysis.Rheumatology (Oxford, England) · 2021Pooled it
- Implants in patients with oral manifestations of autoimmune or muco-cutaneous diseases - A systematic review.Medicina oral, patologia oral y cirugia bucal · 2019Pooled it
- Article
- Oral and Periodontal Manifestations in Systemic Sclerosis: A Comprehensive Review of Pathophysiology, Clinical Features, and Management Strategies.Oral health & preventive dentistry · 2026Review
- Global trends in systemic sclerosis-related mortality, 2001-2023: an epidemiological analysis using World Health Organization mortality data.Clinical rheumatology · 2026Article
- Impact of social deprivation on cancer occurrence and cardiovascular events in systemic sclerosis.Rheumatology advances in practice · 2026Article
- Acute Heart Failure in Advanced Systemic Sclerosis With Multiorgan Involvement.Case reports in cardiology · 2026Article
- The incidence and mortality of connective tissue diseases: a population-level cohort study in England from 2012 to 2023.Rheumatology (Oxford, England) · 2025Article
- Understanding Sex Differences in Autoimmune Diseases: Immunologic Mechanisms.International journal of molecular sciences · 2025Review
- Geographic Clustering of Systemic Sclerosis in Areas of Environmental Pollution.Arthritis care & research · 2025Article
- Baicalin as a potential candidate for treating systemic sclerosis.Inflammopharmacology · 2025Review
- PRDX-4: a novel biomarker similar to KL-6 for predicting the occurrence and progression of systemic sclerosis-ILD.Biomarkers in medicine · 2025Article
- Systemic Sclerosis in a Seven-Year-Old Girl Responding to Mycophenolate Mofetil: A Case Report.Cureus · 2025Article
- A scoping review of the epidemiology of systemic sclerosis and its organ manifestations: 2018-2024.Current opinion in rheumatology · 2025Article
- Extracellular Vesicles as a Potential Biomarker of Pulmonary Arterial Hypertension in Systemic Sclerosis.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Sex differences in systemic sclerosis: from pathogenesis to clinical manifestations and treatment.Therapeutic advances in musculoskeletal disease · 2025Review
- A Scleroderma and Raynaud's UK (SRUK) national survey to explore rheumatologists' awareness, approaches to diagnosis and management and training needs within systemic sclerosis.Rheumatology advances in practice · 2025Article
- Article
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
Abstract
To estimate the incidence, prevalence, and survival of systemic sclerosis in the United Kingdom. We conducted a historical cohort study using data from the Clinical Practice Research Datalink (CPRD). We calculated the incidence and survival of systemic sclerosis between 1994 and 2013 and examined its association with age, sex, and socioeconomic status. We calculated point prevalence on 1 July 2013 and examined its association with the same exposures. We identified 1327 cases with incident systemic sclerosis. Annual incidence was 19.4 per million person-years between 1994 and 2013. The incidence was 4.7 times higher in women than in men, was not influenced by socioeconomic status, and has remained stable over the 20 year study period. The peak age of onset was 55-69 years. Survival at 1, 5, and 10 years was 94.2, 80.0, and 65.7%, respectively. The prevalence was 307 (290-323) per million with the highest prevalence in the 70-84 years age group. We estimate there are currently 1180 new cases of systemic sclerosis each year in the UK, and 19,390 people living with systemic sclerosis. Due to the predicted growth and aging of the population, we predict a 24% increase in incident cases and 26% increase in prevalent cases in 20 years' time. Our estimates of incidence and prevalence are higher than previously reported in the UK, but similar to recent USA and Swedish studies, and do not support a north-south gradient of the occurrence of systemic sclerosis in Europe.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.